Trials / Completed
CompletedNCT00144482
A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy
A Randomized, Double-Blind Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 122 (actual)
- Sponsor
- Chugai Pharmaceutical · Industry
- Sex
- All
- Age
- 20 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the effectiveness and safety in randomized, double-blind, parallel-group study in anemic cancer patients undergoing chemotherapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | recombinant human erythropoietin | 36000IU（0.5mL）s.c./week for 8 weeks |
| DRUG | recombinant human erythropoietin placebo | 0 IU(0.5mL)s.c./week for 8 weeks |
Timeline
- Start date
- 2003-12-01
- Primary completion
- 2005-03-01
- Completion
- 2005-08-01
- First posted
- 2005-09-05
- Last updated
- 2009-02-02
Source: ClinicalTrials.gov record NCT00144482. Inclusion in this directory is not an endorsement.